Cardiol Therapeutics (STU:CT9) Total Stockholders Equity: €14.86 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CT9 Cardiol Therapeutics Inc STU:CT9
30 GF Score
Price €1.86
! 4 Warning Signs
View Full Analysis

What is Cardiol Therapeutics Total Stockholders Equity?

Cardiol Therapeutics STU:CT9 +1.64% 30 Total Stockholders Equity is €14.86 Mil as of Jun. 2026. GuruFocus rates STU:CT9 with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Cardiol Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €14.86 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cardiol Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was €0.13. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cardiol Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

Cardiol Therapeutics  (STU:CT9) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cardiol Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(14.862-0)/115.885
=0.13

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cardiol Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.025 + 0.041) / 14.862
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics Total Stockholders Equity Related Terms

Cardiol Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Cardiol Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics Total Stockholders Equity Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 52.71 36.27 19.31 16.58 11.07

Cardiol Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.49 5.89 11.07 15.26 14.86
STU:CT9
30GF Score
Cardiol Therapeutics Inc STU:CT9
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €14.86 Mil mean?
Cardiol Therapeutics (STU:CT9) has a Total Stockholders Equity of €14.86 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cardiol Therapeutics and its competitors.
Is Cardiol Therapeutics' Total Stockholders Equity too high?
Cardiol Therapeutics' current Total Stockholders Equity is €14.86 Mil. Overall, Cardiol Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Total Stockholders Equity compare to ZTS?
Cardiol Therapeutics' Total Stockholders Equity of €14.86 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cardiol Therapeutics and its competitors. Cardiol Therapeutics's current Total Stockholders Equity is €14.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current Total Stockholders Equity of €14.86 Mil. The current Total Stockholders Equity is €14.86 Mil. Cardiol Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current Total Stockholders Equity is €14.86 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiol Therapeutics Business Description

Other Exchanges CRDL:USACRDL:Canada
Address 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
30GF Score

Get the complete analysis for STU:CT9

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.86
Price